Featured Research

from universities, journals, and other organizations

New Treatment Suitable For All Patients With Least Treatable Brain Tumors, Study Suggests

Date:
January 5, 2008
Source:
Wake Forest University Baptist Medical Center
Summary:
A three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme, a scientists are working on the third -- all targeted to kill or impair cancer cells and spare healthy brain.

New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis. Two of the drug candidates have been developed, and the team is working on the third -- all targeted to kill or impair cancer cells and spare healthy brain.

Related Articles


Waldemar Debinski, M.D., Ph.D., senior researcher and director of the Wake Forest Brain Tumor Center of Excellence, predicts that the cocktail could be tested in patients within five years.

The treatment would be based on the first-ever documented "molecular signature" of GBM tumors. The researchers had previously reported that three different proteins are found in high levels individually in these cancers. In the current study, reported in Clinical Cancer Research, they examined 76 specimens of brain tumor, including 46 GBMs, and nine normal brain samples, to determine how frequently the markers appeared together.

Expression of all three markers was significantly higher in GBM tissue compared to normal brain and to brain tumors that aren't as aggressive as GBM. Particularly important was that all GBM tumors had at least one of the markers present and 95 percent of tumors had at least two.

"This finding offers a unique opportunity for treatment," said Debinski. "Without any pre-therapy testing, we would know for sure that at least one of these targets is highly present in each patient and that the patient is suitable for the combination of off-the-shelf drugs. It is like having a crystal ball."

In a recent issue of Molecular Cancer Therapeutics, the researchers reported developing a potent treatment targeted to one of the proteins (EphA2). In addition, a drug targeted to a second protein, interleukin 13 receptor alpha 2 (IL-13Rƒ2), is already being tested alone in a phase 3 clinical trial. In this trial, the second protein is showing significant benefits to patients, and newer generations are in development. The team is working to develop a drug to target a third marker (Fra-1).

GBM tumors are often resistant to current treatments, including chemotherapy and radiation therapy. The mean survival rate of patients with GBM is about 14 months and has improved only slightly over the past decades.

"Developing molecularly targeted therapies using genetically engineered bacterial toxins represents an attractive option that may improve outcomes," said Debinski.

The fact that the three markers were not found in healthy brain tissue suggests that the proteins are highly suited as targets for therapies designed to kill cancer cells and spare healthy brain tissue. In Molecular Cancer Therapeutics, the team reported success creating a drug to kill cancer cells that have high levels of EphA2. The drug, which would be delivered by catheters directly to the tumor, was created by chemically linking a protein that binds to EphA2 with a modified bacterial toxin.

In the laboratory, the treatment potently killed all of the over-expressing EphA2 cells within 48 hours. It was also effective at reducing tumors in mice. The researchers compared the treatment's potency to the drug Debinski had previously developed to target cells that express IL-13Rƒ2.

"Both were extremely effective and highly potent," said Debinski. "Some of the tumor cells responded to the IL-13 cytotoxin, some responded to EphA2-targeted cytotoxin and some responded to both. This illustrates why we need a cocktail to cover as many patients as possible."

He said this combination treatment might also apply to breast, pancreas and prostate cancers, which also have high levels of these proteins.

The third marker, Fra-1, is believed to control the malignant features of brain tumor cells, such as the development new blood vessels to "feed" the tumor.

An additional benefit of targeting the three proteins is that the drug cocktail affects targets residing in the GBM cellular signaling pathways, including a pathway (epidermal growth factor receptor vIII) that is known to control the expression of all three proteins. These pathways are known to be important in tumor progression.

"With the drug cocktail we may be taking care of cancer cells that are really important for tumor survival," said Debinski. "It may be the best of two worlds."

The research was funded by the National Cancer Institute, National Institute of Neurological Disorders and Wake Forest Brain Tumor Center of Excellence. Co-researchers were Jill Wykosky, Ph.D. candidate, lead author of the two manuscripts, Denise M. Gibo, B.S., and Constance Staton, M.D., all with Wake Forest.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "New Treatment Suitable For All Patients With Least Treatable Brain Tumors, Study Suggests." ScienceDaily. ScienceDaily, 5 January 2008. <www.sciencedaily.com/releases/2008/01/080101093832.htm>.
Wake Forest University Baptist Medical Center. (2008, January 5). New Treatment Suitable For All Patients With Least Treatable Brain Tumors, Study Suggests. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2008/01/080101093832.htm
Wake Forest University Baptist Medical Center. "New Treatment Suitable For All Patients With Least Treatable Brain Tumors, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2008/01/080101093832.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins